Viridian Therapeutics, Inc. (VRDN)

USD 13.3

(10.65%)

Market Cap (In USD)

1.08 Billion

Revenue (In USD)

314 Thousand

Net Income (In USD)

-237.73 Million

Avg. Volume

957.9 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11.4-27.2
PE
-4.33
EPS
-3.07
Beta Value
1.114
ISIN
US92790C1045
CUSIP
92790C104
CIK
1590750
Shares
81485000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen F. Mahoney J.D., MBA
Employee Count
-
Website
https://www.viridiantherapeutics.com
Ipo Date
2014-06-18
Details
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.